Acadia Pharmaceuticals Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021.
According to the Acadia lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
“Acadia Pharmaceuticals Inc.”
If you suffered a loss in Acadia you have until June 21, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.